Physician profile
Tejvir Singh
NPI 1932139136
$86,242.42
in general payments reported to CMS, 2019-2025
77 companies · $5,608 in 2025
The $5,608 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $18K · 2021: $9,503 · 2022: $12K · 2023: $21K · 2024: $7,086 · 2025: $5,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Food and Beverage: $8,328 · Honoraria: $1,088 · Travel and Lodging: $657 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,701.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Food and Beverage | $8,327.83 |
| Honoraria | $1,088.00 |
| Travel and Lodging | $656.89 |
| Education | $281.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17,598.58 | 2019-2024 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $14,064.50 | 2020-2025 | Imfinzi, Tagrisso, Enhertu |
| Incyte Corporation | $6,817.97 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Kite Pharma, INC. | $5,237.08 | 2020-2023 | Tecartus, Yescarta |
| Exelixis INC. | $4,609.06 | 2019-2025 | Cabometyx |
| Dova Pharmaceuticals | $3,919.70 | 2019 | |
| Pfizer INC. | $3,621.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,174.28 | 2019-2025 | Opdivo, Opdualag |
| Pharmacosmos Therapeutics INC. | $2,400.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $2,239.87 | 2019-2025 | Scemblix |
| Daiichi Sankyo INC. | $2,006.35 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Coherus Oncology, INC. | $1,988.00 | 2021-2023 | |
| Lilly USA, LLC | $1,860.43 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $1,851.67 | 2023-2024 | |
| Beigene USA, INC. | $1,647.48 | 2020-2024 | Brukinsa |
Show all 76 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejvir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.